All-cause health care costs during the post-index period were 6.5% greater for the vial/syringe cohort in the MarketScan database. In the LifeLink database, all-cause health care costs were 2.7% greater in the vial/syringe cohort than in the pen cohort, but the difference was not statistically significant.

The researchers concluded, “Although insulin pens are associated with greater acquisition costs than vials/syringes, the greater cost of health care associated with vial/syringe use in two independent database analyses demonstrates the cost advantage of pens over vials/syringes.”


Continue Reading

References

1. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218-1224.

2. Asche CV, Luo W, Aagren M. Differences in rates of hypoglycemia and healthcare costs in patients treated with insulin aspart in pens versus vials. Curr Med Res Opin.2013;29(10):1287-1296.

3. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med. 2008;25(3):245-254.

4. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.

5. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74-109.

6. Asche CV, Shane-McWhorter L, Raparla S. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence. Diabetes Technol Ther. 2010;12 Suppl 1:S101-S108.

7. Baser O, Bouchard J, DeLuzio T, et al. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe. Adv Ther. 2010;27(2):94-104.

8. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two  insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-496.

9. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther. 2006;28(10):1712-1725.

10. Cobden D, Lee WC, Balu S,. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007;27(7):948-962.

11. Pawaskar MD, Camacho FT, Anderson RT. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther. 2007;29 Spec No:1294-1305.